Trial · NCT04086121
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 32
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Spesolimab 600 mg | 1 | 14 | |
| other | Neutropenia | Blood and lymphatic system disorders | Spesolimab 600 mg | 1 | 14 | |
| other | Atrial fibrillation | Cardiac disorders | Spesolimab 600 mg | 1 | 14 | |
| other | Drug hypersensitivity | Immune system disorders | Spesolimab 600 mg | 1 | 14 | |
| other | Asymptomatic COVID-19 | Infections and infestations | Spesolimab 600 mg | 1 | 14 | |
| other | Cellulitis | Infections and infestations | Spesolimab 600 mg | 2 | 14 | |
| other | Nasopharyngitis | Infections and infestations | Spesolimab 600 mg | 3 | 14 | |
| other | Skin infection | Infections and infestations | Spesolimab 600 mg | 1 | 14 | |
| other | Soft tissue infection | Infections and infestations | Spesolimab 600 mg | 1 | 14 | |
| other | Tinea pedis | Infections and infestations | Spesolimab 600 mg | 1 | 14 | |
| other | Tinea versicolour | Infections and infestations | Spesolimab 600 mg | 1 | 14 | |
| other | Upper respiratory tract infection | Infections and infestations | Spesolimab 600 mg | 2 | 14 | |
| other | Upper respiratory tract infection bacterial | Infections and infestations | Spesolimab 600 mg | 1 | 14 | |
| other | Urinary tract infection | Infections and infestations | Spesolimab 600 mg | 1 | 14 | |
| other | Foot fracture | Injury, poisoning and procedural complications | Spesolimab 600 mg | 1 | 14 | |
| other | Joint injury | Injury, poisoning and procedural complications | Spesolimab 600 mg | 1 | 14 | |
| other | Skin laceration | Injury, poisoning and procedural complications | Spesolimab 600 mg | 1 | 14 | |
| other | Splinter | Injury, poisoning and procedural complications | Spesolimab 600 mg | 1 | 14 | |
| other | Vitamin B12 decreased | Investigations | Spesolimab 600 mg | 1 | 14 | |
| other | Diabetes mellitus inadequate control | Metabolism and nutrition disorders | Spesolimab 600 mg | 1 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04086121/events